Earnings Releases·Nov 3, 2026, 8:07 AM ET

Pfizer Inc. — Third Quarter 2026 Earnings Summary

Total revenues for Q3 2026 reached $16.6 billion, flat year-over-year operationally, while revenue from launched and acquired products grew 32% operationally; adjusted diluted EPS was $0.87, flat year-over-year.
Management raised full-year 2026 revenue guidance to $62.0–$64.0 billion and adjusted diluted EPS guidance to $2.95–$3.05, citing strong commercial momentum despite an assumed $1.1 billion revenue impact from generic and biosimilar competition.
Strategic capital allocation included $7.3 billion returned to shareholders via dividends in the first nine months of 2026, with no share repurchases completed and $3.3 billion remaining in authorization.
R&D investment remained robust with $3.0 billion spent in Q3 (up 18% operationally) and $8.3 billion in the first nine months, including $850 million in business development transactions such as the Innovent Biologics deal.
Key product performance showed mixed results: Oncology revenues grew 10% driven by Padcev and Lorbrena, while Primary Care revenues declined 9% due to declines in Comirnaty and Paxlovid, partially offset by 25% growth in Eliquis.